390 related articles for article (PubMed ID: 37465682)
41. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
42. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
43. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
[TBL] [Abstract][Full Text] [Related]
44. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine.
Li W; Zhao T; Tao B; Zhao L; Xiao H; Ding X; Li C; Chen L; Cheng H; Lou Y; Chen Y; Wu C
Hum Vaccin Immunother; 2023 Aug; 19(2):2264589. PubMed ID: 37846840
[TBL] [Abstract][Full Text] [Related]
45. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ
mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
47. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G;
Front Immunol; 2023; 14():1104124. PubMed ID: 36776853
[TBL] [Abstract][Full Text] [Related]
48. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
49. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
50. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
Abu Shqara R; Frank Wolf M; Mikhail Mustafa S; Sgayer I; Assulyn T; Abu Zraki A; Askhar Majadla N; Rechnizter H; Shehadeh M; Fleisher Sheffer V; Bordeynik-Cohen M; Yakir O; Lowenstein L; Sela E; Edelstein M; Dror AA
Am J Perinatol; 2024 May; 41(S 01):e1935-e1943. PubMed ID: 37164317
[TBL] [Abstract][Full Text] [Related]
51. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine.
Kotaki R; Adachi Y; Moriyama S; Onodera T; Fukushi S; Nagakura T; Tonouchi K; Terahara K; Sun L; Takano T; Nishiyama A; Shinkai M; Oba K; Nakamura-Uchiyama F; Shimizu H; Suzuki T; Matsumura T; Isogawa M; Takahashi Y
Sci Immunol; 2022 Apr; 7(70):eabn8590. PubMed ID: 35113654
[TBL] [Abstract][Full Text] [Related]
52. Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia.
Zapata-Cardona MI; Flórez-Álvarez L; Lopera TJ; Chvatal-Medina M; Zapata-Builes W; Diaz FJ; Aguilar-Jimenez W; Taborda N; Hernandez JC; Rugeles MT
Front Immunol; 2022; 13():1102384. PubMed ID: 36618393
[TBL] [Abstract][Full Text] [Related]
53. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
[TBL] [Abstract][Full Text] [Related]
54. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332
[TBL] [Abstract][Full Text] [Related]
55. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.
Seery V; Raiden S; Russo C; Borda M; Herrera L; Uranga M; Varese A; Marcó Del Pont M; Chirino C; Erramuspe C; Álvarez LS; Lenoir M; Morales LD; Davenport C; Alarcón Flores A; Huespe Auchter S; Ruiz Y; Monsalvo L; Sastoque L; Gavazzi M; Mazzitelli I; Di Diego F; Longueira Y; Mazzitelli B; Sananez I; De Carli N; Biglione MM; Gómez Penedo JM; Ceballos A; Laufer N; Ferrero F; Geffner J; Arruvito L
EBioMedicine; 2022 Sep; 83():104230. PubMed ID: 35988465
[TBL] [Abstract][Full Text] [Related]
56. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy.
Nir O; Schwartz A; Toussia-Cohen S; Leibovitch L; Strauss T; Asraf K; Doolman R; Sharabi S; Cohen C; Lustig Y; Regev-Yochay G; Yinon Y
Am J Obstet Gynecol MFM; 2022 Jan; 4(1):100492. PubMed ID: 34547533
[TBL] [Abstract][Full Text] [Related]
57. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
[TBL] [Abstract][Full Text] [Related]
58. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis.
Song YC; Liu SJ; Lee HJ; Liao HC; Liu CT; Wu MY; Yen HR
J Microbiol Immunol Infect; 2023 Aug; 56(4):705-717. PubMed ID: 37055256
[TBL] [Abstract][Full Text] [Related]
59. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
